1The semiconductor unwind went into biotech, not into cash
The Nasdaq opened about 3% lower on 23 June, and the selling sat almost entirely in one place: , and each fell 7–8% in a semiconductor-led drop, with and lower alongside them. What the rest of the tape did is the more useful fact. The S&P 500 was down around 1%, the Russell 2000 down a quarter of a percent, and the Dow finished higher. Money left one sector. It did not leave the market.
Ross Givens, in a video titled "Wall Street Is Panic Selling... I'm Buying This $3 Stock," puts the cause as overextension rather than damage: semis had run 108% in six months, which he treats as a move that had to give something back. His read on where the money went is biotech, which was rising while the index fell, and he backed that with size — 5,000 shares of (Iovance Biotherapeutics, roughly a $2bn company) on a breakout from a consolidation base, stopped at the session low about 10% below, plus and the 2× leveraged as broader expressions of the same rotation.
The day's separately sourced screens point the same way without being asked to. and were among the pre-market biotech risers on Yahoo Finance's gainer list, with carrying the quantum side, while , and led the decliners. That corroborates the direction of the flow; it says nothing about the individual names.
Two things temper the call itself. The case is entirely chart-and-momentum — breakouts, bases, average daily ranges — with no earnings or pipeline work shown behind any of it; the same video passed on because its 2.8% average daily range was too slow to trade, which is a criterion about the chart, not a view on the company. And the video runs a paid-service promotion, so the picks arrive attached to a sales pitch. The rotation itself is evidenced by the tape. The four names are one chart reader's expression of it, and a single session's divergence is not yet a trend — the test is whether biotech keeps its bid on a day when semis stop falling.
2The forced index bid for SpaceX lands weeks before the lockup that quintuples its float
Felix, on Felix & Friends, set out a two-stage supply argument on that does not need a market view to work. Stage one is index inclusion, which he sizes at roughly $22–30bn of passive buying that has to clear through early July — buyers with no discretion about price. Stage two is 11 August, when the first lockup expires and the free float goes from 5% to 25%: five times the tradeable supply arriving in a day, into whatever demand is left once the forced bid has been filled. The day's news coverage carried the same mechanics, framed as a $600bn swing around a roughly $2trn valuation.
His analogue is Facebook's 2012 first lockup, after which the stock halved. He then stacks three more — the Nifty Fifty in 1973–74, the dot-com drawdown of 78%, and Japan in 1989 with its thirty-year round trip — and the stacking makes the argument weaker rather than stronger. Four crashes selected after the fact are a mood, not a base rate. The lockup arithmetic stands on its own; the montage is decoration.
The concentration point underneath it is the more durable half. The top ten S&P 500 names are about 40% of the index, roughly double the 1990–2015 norm, which he renders as "your index fund is now a tech fund" — a claim aimed at , and holders who never chose that exposure. Note the gap between the framing and the instruction: 11 August is billed as the most dangerous day, the video funnels toward a free teaching session, and yet the actual advice is to review or trim only if it exceeds 5–10% of a portfolio, set alerts, and explicitly not to sell broad index funds. No buy ticker is named anywhere in it; his own diversification is given as categories, "apparel companies, pipeline companies," rather than as names.
What makes this worth keeping is that both legs are dated. Passive buying through early July, a five-fold supply increase on 11 August. Either the price behaves around those dates or the mechanism is weaker than claimed, and neither outcome depends on the crash history being relevant.
3Hike bets and a cooling Hormuz standoff put the dollar at a one-year high and gold at a two-week low
Reuters copy carried twice through the day's news feed had rate-hike bets in focus rather than cuts, with the dollar at a one-year high and gold at a two-week low — the two prices that move first when a rate path is being repriced upward. Yahoo Finance carried Fed Chair Kevin Warsh's commentary on inflation and AI into the same session.
The geopolitical leg is pulling the other way on risk and the same way on the dollar. The Senate joined the House in a vote to halt the Iran action, and Oman–Iran talks on Hormuz navigation were under way, with crude sliding on the de-escalation. A hawkish rate read and a calming Gulf are unrelated causes arriving at compatible prices: dollar up, gold down, crude down.
The day's news pull did contradict itself on oil, which is worth naming. One Google News item still in circulation was dated 3 June and reported oil rebounding, against wire items dated 24 June reporting crude sliding. The fresher copy is the one describing today — and the day's undirected mention list still carried (Kosmos Energy) up 10% on a crude recovery, the opposite direction to that freshest reporting. Dates settle it, not headlines.
If the Hormuz talks stall, the crude leg reverses on its own, without anything happening to the rate leg. Two independent stories currently agreeing is not one story.
What the sources recommended
Seven calls came out of two videos, six of them from the same one, and three of the four buys are the same biotech rotation in different wrappers.
The buys, all from Ross Givens. (Iovance Biotherapeutics) — 5,000 shares bought on a breakout, stop at the day's low, roughly 10% below, horizon weeks. (iShares Biotech ETF) and (a 2× leveraged Nasdaq biotech ETF) as the sector and the aggressive version of the same idea. Separately (SEALSQ, quantum-resistant security chips) — 10,000 shares around $3.12 against a target near $4, on the catalyst of two quantum-computing executive orders, horizon days to weeks. The caveat from the first section attaches to all four: technical basis only, and a paid service promoted in the same video.
The sells, and none of them is a full exit. is a conditional trim from Felix — only if the position runs past 5–10% of a portfolio, and paired with an explicit instruction to leave broad index funds alone. (Applied Optoelectronics) and (Outlook Therapeutics) are partial profit-taking on winners: has doubled since a May entry, is up 130–140% on an FDA second look.
Tonight's Micron print lands in the middle of the semiconductor argument
reports after the close — the bellwether of the sector that just fell 7–8% in a session, and the nearest thing to a test of whether that drop was positioning or fundamentals. also reports after the close, with , and before the open and and alongside. Warsh's inflation-and-AI commentary is the macro item to read against the hike pricing above. , and follow tomorrow.
Three mechanical moves are worth separating from all of that: replaces in the Dow, raised its buyback to $7.5bn, and goes through a one-for-three reverse split. Index and corporate-action events, not demand signals.
